Post on 14-Aug-2015
transcript
European and Developing Countries Clinical Trials
Partnership (EDCTP)
Prepared by Sirpa Nuotio, Academy of Finland
EDCTP
Created in 2003 as a European Response to the
global health crisis caused by HIV/AIDS,tuberculosis and malaria
EDCTP1 in a nutshell
Number of projects: 246•259 institutions participate and receiving funds from EDCTP•3442 posts are supported on EDCTP grants•Total grant value € 382 MClinical trials: 100Training of scientists: 514Publications: 485
The second EDCTPprogramme (EDCTP2)
• EDCTP2 will operate from 2014-2024 (part of H2020)
• New legal entity EDCTP Association
• Governance: General Assembly and Board
• Offices based in the Netherlands and South Africa)
Funding
FundingFinland = 2 million €
EDCTP2: building on thecurrent programme
• Support the whole range of clinical research through broad, non-prescriptive, open calls: phase I-IV clinical trials
• Strengthen the “enabling environment” to conduct clinical research and implementation research in Africa
• Participate in large, multi-funder projects on specific activities in HIV/AIDS, TB, malaria, NIDs and implementation research on health services optimisation
• Align and partner with governments, funders and other global initiatives on PRDs for achieving an enhancing and multiplier effect
• Geographical focus on sub-Saharan Africa
EDCTP2 Participating States (current situation)
• European countries: Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Switzerland
• African countries: Congo, Cameroon, Gambia, Ghana, Mozambique, Niger, Senegal, South Africa, Tanzania, Uganda, Zambia
Countries that can receive funding in integrated activities
• All sub-Saharan African countries• All EU Member States and
Associated Countries
Next steps
• High-level launch of EDCTP2 on 1-3 December 2014 in Cape Town, South Africa
• 2014 Calls for proposals pre-published in October and will be open in Q4 2014
Calls
Horizon 2020 Health 2014-2015 PHC 8 – 2014: Vaccine development for poverty-related and neglected infectious diseases: TuberculosisPHC 9 – 2015: Vaccine development for poverty-related and neglected infectious diseases: HIV/AIDS
More Information
• EDCTP Websitewww.edctp.org
• Academy of FinlandSirpa NuotioSirpa.nuotio@aka.fi